Skin autofluorescence as a tool for cardiovascular risk estimation in patients with rheumatoid arthritis

References

1. • Aviña-Zubieta J.A.
   • Choi H.K.
   • Sadatsafavi M.
   • Etminan M.
   • Esdaile J.M.
   • Lacaille D.
   Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.
   Arthritis Rheum. 2008; 59: 1690-1697
   View in Article

   • Google Scholar
2. • Crowson C.S.
   • Rollefstad S.
   • Ikdahl E.
   • Kitas G.D.
   • van Riel P.L.C.M.
   • Gabriel S.E.
   • et al.
   On behalf of a trans-Atlantic cardiovascular consortium for rheumatoid arthritis (ATACC-RA). Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.
   Ann Rheum Dis. 2018; 77: 48-54https://doi.org/10.1136/annrheumdis-2017-211735
   View in Article

   • Google Scholar
3. • Dixon W.G.
   • Watson K.D.
   • Lunt M.
   • Dixon W.G.
   • Watson K.D.
   • Lunt M.
   • et al.
   British Society for Rheumatology Biologics Register Control Centre Consortium, British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology biologics register.
   Arthritis Rheum. 2007; 56: 2905-2912
   View in Article

   • Google Scholar
4. • Quality Institute for Health (CBO)
   Dutch General Practitioner society (NHG) Multidisciplinary guideline on cardiovascular risk management.
   https://www.nhg.org/?q=standaarden/volledig/cardiovasculair-risicomanagement

   Date: 2011

   Date accessed: August 30, 2018
   View in Article

   • Google Scholar
5. • Perk J.
   • De Backer G.
   • Gohlke H.
   • Graham I.
   • Reiner Z.
   • Verschuren M.
   • et al.
   European guidelines on CVD practices in clinical practice (2012).
   Eur Heart. 2012; 33: 1635-1701
   View in Article

   • Google Scholar
6. • Meerwaldt R.
   • Graaff R.
   • Oomen P.H.
   • Links T.P.
   • Jager J.J.
   • Alderson N.L.
   • et al.
   Simple non-invasive assessment of advanced glycation endproduct accumulation.
   Diabetologia. 2004; 47: 1324-1330
   View in Article

   • Google Scholar
7. • Waateringe van R.P.
   • Slagter S.N.
   • Beek van A.P.
   • van der Klauw M.M.
   • van Vliet-Ostaptchouk J.V.
   • Graaff R.
   • et al.
   Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components.
   Diabetol Metab Syndr. 2017; 9: 42
   View in Article

   • Google Scholar
8. • Waateringe van R.P.
   • Fokkens B.T.
   • Slagter S.N.
   • van der Klauw M.M.
   • van Vliet-Ostaptchouk J.V.
   • Graaff R.
   • et al.
   Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population.
   Diabetologia. 2019 Feb; 62 ([Epub 2018 Nov]): 269-280https://doi.org/10.1007/s00125-018-4769-x
   View in Article

   • Google Scholar